消化系统类药物

Search documents
向日葵拟收购兮璞材料100%股权及贝得药业40%股权 股票复牌
Zhi Tong Cai Jing· 2025-09-22 06:56
本次交易有利于进一步提高上市公司资产质量,促进上市公司的长远发展。本次交易完成后,上市公司 将切入到高端半导体材料领域,打造第二增长曲线,加快向新质生产力转型步伐,增加新的利润增长 点,从而进一步提高上市公司持续盈利能力。 向日葵(300111)(300111.SZ)发布公告,公司拟通过发行股份及支付现金的方式向上海兮噗等6名交易 对方购买其合计持有的兮璞材料100%股权,向向日葵投资购买其持有的贝得药业40%股权,并募集配 套资金。公司股票将于2025年9月22日(星期一)上午开市起复牌。 兮璞材料主要从事高端半导体材料的研发、制造与销售,主要产品包括半导体级高纯度电子特气、硅基 前驱体、金属基前驱体等,广泛应用于半导体制造过程中的扩散、蚀刻、薄膜沉积等关键工艺环节。贝 得药业作为向日葵的控股子公司,主要从事抗感染类、心血管类、消化系统类等药物的研发、制造和销 售。 ...
9月22日早间重要公告一览
Xi Niu Cai Jing· 2025-09-22 03:50
Group 1 - Global Printing announced that shareholder Hong Kong Yuanshi International Co., Ltd. plans to reduce its stake by up to 3.2004 million shares, accounting for 1% of the total share capital, due to personal funding needs [1] - Sunflower intends to acquire 100% equity of Xi Pu Materials and 40% equity of Zhejiang Beid Pharmaceutical through a combination of share issuance and cash payment, with stock resuming trading on September 22, 2025 [1][2] - Crown Zhong Ecology is planning a change in control, leading to a temporary suspension of its stock and convertible bonds due to significant uncertainties [2] Group 2 - China Oil Engineering's wholly-owned subsidiary signed a $513 million EPC contract for an LNG pipeline project in the UAE, covering approximately 180.5 kilometers of natural gas pipeline with a 36-month construction period [3] - Shanxi Fenjiu announced that shareholder Huachuang Xinrui (Hong Kong) Co., Ltd. plans to reduce its stake by up to 16.2006 million shares, representing no more than 1.33% of the total share capital [4] - Brother Technology's subsidiary received a drug registration certificate for Iopamidol injection, which is included in the national medical insurance catalog [5] Group 3 - Lin Yang Energy is expected to win a bid for a metering equipment project from the State Grid, with an estimated total bid amount of approximately 142 million yuan [6] - Huahai Chengke received approval from the China Securities Regulatory Commission for issuing shares and convertible bonds to purchase assets and raise no more than 800 million yuan in matching funds [8] - Jindi Co. signed a framework agreement to acquire controlling interest in Unico Precision, which specializes in manufacturing gears and automotive parts [10] Group 4 - Ruifeng High Materials announced that its major shareholder plans to reduce its stake by up to 2.4 million shares, accounting for 0.9584% of the total share capital [12] - Changliang Technology's director plans to reduce his stake by 1.05 million shares, representing 0.129% of the total share capital [14] - Zhongjing Food's director plans to reduce his stake by up to 150,000 shares, accounting for 0.10% of the total share capital [16] Group 5 - Haitai Technology announced that two shareholders plan to reduce their stakes by a total of up to 2.53% of the total share capital [18] - Zhenlei Technology's chairman is under detention but the company states that control has not changed and operations remain normal [20] - Huakang Co. plans to distribute a cash dividend of 0.2 yuan per share, totaling approximately 60.61 million yuan [19]
向日葵(300111.SZ)拟收购兮璞材料100%股权及贝得药业40%股权 股票复牌
智通财经网· 2025-09-21 08:25
本次交易有利于进一步提高上市公司资产质量,促进上市公司的长远发展。本次交易完成后,上市公司 将切入到高端半导体材料领域,打造第二增长曲线,加快向新质生产力转型步伐,增加新的利润增长 点,从而进一步提高上市公司持续盈利能力。 智通财经APP讯,向日葵(300111.SZ)发布公告,公司拟通过发行股份及支付现金的方式向上海兮噗等6 名交易对方购买其合计持有的兮璞材料100%股权,向向日葵投资购买其持有的贝得药业40%股权,并 募集配套资金。公司股票将于2025年9月22日(星期一)上午开市起复牌。 兮璞材料主要从事高端半导体材料的研发、制造与销售,主要产品包括半导体级高纯度电子特气、硅基 前驱体、金属基前驱体等,广泛应用于半导体制造过程中的扩散、蚀刻、薄膜沉积等关键工艺环节。贝 得药业作为向日葵的控股子公司,主要从事抗感染类、心血管类、消化系统类等药物的研发、制造和销 售。 ...
向日葵:拟购买高端半导体材料公司兮璞材料100%股权等资产 股票9月22日复牌
Zheng Quan Shi Bao Wang· 2025-09-21 07:51
转自:证券时报 人民财讯9月21日电,向日葵(300111)9月21日公告,公司拟以发行股份及支付现金的方式购买漳州兮璞 材料科技有限公司(简称"兮璞材料")100%股权、浙江贝得药业有限公司40%股权并募集配套资金。 公司股票将于2025年9月22日复牌。兮璞材料主要从事高端半导体材料的研发、制造与销售,主要产品 包括半导体级高纯度电子特气、硅基前驱体、金属基前驱体等,广泛应用于半导体制造过程中的扩散、 蚀刻、薄膜沉积等关键工艺环节。贝得药业作为向日葵的控股子公司,主要从事抗感染类、心血管类、 消化系统类等药物的研发、制造和销售。 ...